Female shock patients face delays in treatment and are less likely to receive approved interventions, says Suzanne Baron.

This explains at least some of the racial/ethnic gaps in survival, researchers say. Harder to pinpoint is exactly why ...

With new CVD treatments arriving each year, “there’s no reason why outcomes should be getting worse,” says Jason Wasfy.

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended ...

Should we stop anticoagulation therapy before TAVI in patients with aortic stenosis? Dirk-Jan van Ginkel and C. Michael ...

Thinking outside the box is needed to spark greater enrollment of women in research endeavors historically dominated by men.

1. Be compulsive about your patients. Take no shortcuts. 2. Be curious about why we’re doing something. If there is no good ...

The results suggest potential harm when leaving patients who’ve received ultrathin-strut stents on DAPT beyond 1 year.

An initial PINGS pilot trial performed by Ovbiagele’s group in Ghana demonstrated the feasibility of deploying a nurse-guided ...

Researchers say the data further support the use of an FFR-first strategy in treating intermediate coronary lesions.

Our most-read articles explore “occlusion MI” versus STEMI, TAVI in asymptomatic AS, and highlights from recent conferences.

The lower rate of net adverse clinical events was driven by less bleeding in those on 1 month of prasugrel-based DAPT.